Discovery of Pyridinone Derivatives as Potent, Selective, and Orally Bioavailable Adenosine A<sub>2A</sub> Receptor Antagonists for Cancer Immunotherapy
作者:Chenyu Zhu、Shuyin Ze、Ronghui Zhou、Xinyu Yang、Haojie Wang、Xiaolei Chai、Meimiao Fang、Mingyao Liu、Yonghui Wang、Weiqiang Lu、Qiong Xie
DOI:10.1021/acs.jmedchem.2c01860
日期:——
of adenosine A2A receptor (A2AR) antagonists as novel approaches for cancer immunotherapy. By screening our in-house compound library, a pyridinone hit compound (1) with weak A2AR antagonistic activity was identified. Further structure–activity relationship studies revealed a series of pyridinone derivatives with strong potency. Compound 38 stood out with a potent A2AR antagonistic activity (IC50 =
最近的研究和临床证据强烈支持开发腺苷 A 2A受体 (A 2A R) 拮抗剂作为癌症免疫治疗的新方法。通过筛选我们的内部化合物库,鉴定出具有弱 A 2A R 拮抗活性的吡啶酮命中化合物 ( 1 ) 。进一步的构效关系研究揭示了一系列具有强大效力的吡啶酮衍生物。化合物38具有强大的 A 2A R 拮抗活性(IC 50 = 29.0 nM)、良好的小鼠肝微粒体代谢稳定性(t 1/2 = 86.1 分钟)和出色的口服生物利用度(F= 86.1%)。值得注意的是,38通过下调免疫抑制分子(LAG-3和TIM-3)和上调效应分子(GZMB、IFNG和IL-2)有效增强了体外 T 细胞的激活和杀伤能力。此外,38在 MC38 肿瘤模型中通过口服给药表现出优异的体内抗肿瘤活性,肿瘤生长抑制 (TGI) 为 56.0%,证明其作为癌症免疫治疗的新型 A 2A R 拮抗剂候选物的潜力。